KR101070036B1 - 골관절염에 대한 칼시토닌의 용도 - Google Patents

골관절염에 대한 칼시토닌의 용도 Download PDF

Info

Publication number
KR101070036B1
KR101070036B1 KR1020067001391A KR20067001391A KR101070036B1 KR 101070036 B1 KR101070036 B1 KR 101070036B1 KR 1020067001391 A KR1020067001391 A KR 1020067001391A KR 20067001391 A KR20067001391 A KR 20067001391A KR 101070036 B1 KR101070036 B1 KR 101070036B1
Authority
KR
South Korea
Prior art keywords
calcitonin
salmon
osteoarthritis
cnac
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067001391A
Other languages
English (en)
Korean (ko)
Other versions
KR20060034298A (ko
Inventor
모이즈 아지리아
클라우스 크리스티안센
사이몬 데이비드 베이츠만
슈펭 리
Original Assignee
노르딕 바이오사이언스 에이/에스
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101070036(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노르딕 바이오사이언스 에이/에스, 노파르티스 아게 filed Critical 노르딕 바이오사이언스 에이/에스
Publication of KR20060034298A publication Critical patent/KR20060034298A/ko
Application granted granted Critical
Publication of KR101070036B1 publication Critical patent/KR101070036B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020067001391A 2003-07-23 2004-07-22 골관절염에 대한 칼시토닌의 용도 Expired - Fee Related KR101070036B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48940003P 2003-07-23 2003-07-23
US60/489,400 2003-07-23

Publications (2)

Publication Number Publication Date
KR20060034298A KR20060034298A (ko) 2006-04-21
KR101070036B1 true KR101070036B1 (ko) 2011-10-04

Family

ID=34135096

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067001391A Expired - Fee Related KR101070036B1 (ko) 2003-07-23 2004-07-22 골관절염에 대한 칼시토닌의 용도

Country Status (22)

Country Link
US (3) US7749954B2 (enExample)
EP (2) EP1651249B1 (enExample)
JP (2) JP4716987B2 (enExample)
KR (1) KR101070036B1 (enExample)
CN (1) CN1856321B (enExample)
AU (2) AU2004262906B2 (enExample)
BR (1) BRPI0412265A (enExample)
CA (1) CA2532565C (enExample)
ES (2) ES2436152T3 (enExample)
IL (2) IL173002A (enExample)
IS (1) IS8316A (enExample)
MA (1) MA27929A1 (enExample)
MX (1) MXPA06000807A (enExample)
NO (1) NO330867B1 (enExample)
NZ (1) NZ544645A (enExample)
PL (2) PL1651249T3 (enExample)
PT (2) PT2316473E (enExample)
RU (1) RU2368390C2 (enExample)
TN (1) TNSN06022A1 (enExample)
TW (1) TWI343816B (enExample)
WO (1) WO2005014031A1 (enExample)
ZA (1) ZA200600373B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190036903A (ko) 2017-09-28 2019-04-05 (주)휴럼 리트세노라이드를 유효성분으로 하는 염증과 골관절염에 대한 예방 및 치료용 약학 조성물

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04005080A (es) * 2004-05-27 2005-11-30 Aspid S A De C V Una composicion moduladora de la inflamacion articular cronica a base de colagena-polivinilpirrolidona.
JP2009508875A (ja) * 2005-09-19 2009-03-05 エミスフェアー・テクノロジーズ・インク Ｎ−（５−クロロサリチロイル）−８−アミノカプリル酸二ナトリウム塩の結晶形
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
RU2469709C2 (ru) * 2005-11-17 2012-12-20 Новартис Аг Фармацевтическая композиция
EP2059260B1 (en) 2006-08-31 2013-06-19 Novartis AG Pharmaceutical compositions comprising hGH for oral delivery
AU2008223108B2 (en) * 2007-03-02 2013-10-10 Novartis Ag Oral administration of a calcitonin
EP2185136A2 (en) * 2007-08-09 2010-05-19 Novartis Ag Oral calcitonin compositions and applications thereof
PL2215047T3 (pl) 2007-11-02 2014-05-30 Emisphere Tech Inc Sposób leczenia niedoborów witaminy b12
AU2009283821B2 (en) 2008-08-18 2014-05-29 Entera Bio Ltd. Methods and compositions for oral administration of proteins
CN102369018B (zh) * 2009-03-12 2016-08-03 关键生物科学有限公司 糖尿病和代谢综合征的治疗
WO2011067283A1 (en) 2009-12-01 2011-06-09 Novo Nordisk A/S Novel peptidyl alpha-hydroxyglycine alpha-amidating lyases
US20120071410A1 (en) 2010-09-21 2012-03-22 Unigene Laboratories Inc. Calcitonin products and therapies for treating inflammatory or degenerative diseases
EP2773365B1 (en) 2011-11-02 2016-07-20 KeyBioscience AG Peptide analogs for treating diseases and disorders
CN103998052B (zh) 2011-11-02 2016-08-17 关键生物科学有限公司 用于治疗疾病和紊乱的肽类似物
AU2013234096B2 (en) * 2012-03-16 2018-08-09 Fertility Innovations Limited Processing of sperm cells
JP6639389B2 (ja) 2013-11-14 2020-02-05 キーバイオサイエンス・アクチエンゲゼルシャフト 疾患および障害を処置するためのカルシトニン模倣体
CN104095828A (zh) * 2014-07-29 2014-10-15 中国药科大学 一种降钙素口服肠溶组合物及其制备方法
GB201500263D0 (en) 2015-01-08 2015-02-25 Keybioscience Ag Calcitonin analogues for treating diseases and disorders
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
GB201704429D0 (en) 2017-03-21 2017-05-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
GB201707955D0 (en) 2017-05-18 2017-07-05 Keybioscience Ag Dual amylin and calcitonin receptor agonists for treating diseases and disorders
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US11274158B2 (en) * 2018-01-30 2022-03-15 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
CN108586601B (zh) * 2018-05-14 2021-07-27 四川大学 一种骨靶向性鲑鱼降钙素及其制备方法
GB201813678D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Acylated calcitonin mimetics
GB201813677D0 (en) 2018-08-22 2018-10-03 Keybioscience Ag Calcitonin mimetics for treating diseases and disorders
JP2023515886A (ja) 2020-03-02 2023-04-14 マジック リープ， インコーポレイテッド 没入型のオーディオプラットフォーム

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US608618A (en) 1898-08-09 Thomas millen
HU203204B (en) 1987-09-15 1991-06-28 Sandoz Ag Process for producing suppository containing calcitonin and taurocholic acid
JP3501471B2 (ja) 1992-06-15 2004-03-02 旭化成ファーマ株式会社 カルシトニン類の安定化組成物および安定化法
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
TW448172B (en) * 1996-03-08 2001-08-01 Pharmacia & Upjohn Co Llc Novel hydroxamic acid derivatives useful for the treatment of diseases related to connective tissue degradation
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
GB9623205D0 (en) * 1996-11-07 1997-01-08 Eurand Int Novel pharmaceutical compositions
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2369591C (en) * 1999-04-05 2011-06-14 Emisphere Technologies, Inc. Disodium salts, monohydrate, and ethanol solvates
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6380405B1 (en) 1999-09-13 2002-04-30 Nobex Corporation Taxane prodrugs
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
US20020012459A1 (en) 2000-06-22 2002-01-31 Chips Brain Co. Ltd. Method and apparatus for detecting stereo disparity in sequential parallel processing mode
DE60141520D1 (de) 2000-08-29 2010-04-22 Biocon Ltd 5-asa-derivate mit entzündungshemmender und antibiotischer wirkung und verfahren zur behandlung von krankheiten mit diesen derivaten
CA2426730A1 (en) 2000-10-25 2002-05-16 Smithkline Beecham Corporation Calcilytic compounds
US7049283B2 (en) * 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
US6479692B1 (en) 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
PT1420827E (pt) 2001-08-17 2009-12-15 Novartis Ag 5-cnac como agente de administração oral de fragmentos da hormona paratiróide

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Boll. Soc. It. Biol. Sper. Vol.68(2):85-89 (1992).
Clinica Terapeutica Vol.110(2):129-133 (1984).

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190036903A (ko) 2017-09-28 2019-04-05 (주)휴럼 리트세노라이드를 유효성분으로 하는 염증과 골관절염에 대한 예방 및 치료용 약학 조성물

Also Published As

Publication number Publication date
HK1089935A1 (en) 2006-12-15
BRPI0412265A (pt) 2006-09-05
WO2005014031A1 (en) 2005-02-17
US20060194722A1 (en) 2006-08-31
AU2008202879A1 (en) 2008-07-24
PT1651249E (pt) 2012-12-21
TWI343816B (en) 2011-06-21
RU2006105479A (ru) 2007-09-10
PT2316473E (pt) 2013-09-20
CA2532565A1 (en) 2005-02-17
MA27929A1 (fr) 2006-06-01
MXPA06000807A (es) 2006-08-23
TNSN06022A1 (en) 2007-10-03
US20100278881A1 (en) 2010-11-04
EP2316473B1 (en) 2013-08-21
KR20060034298A (ko) 2006-04-21
ES2398237T3 (es) 2013-03-14
IL173002A0 (en) 2006-06-11
NO20060890L (no) 2006-04-24
AU2004262906B2 (en) 2008-04-03
CN1856321A (zh) 2006-11-01
NO330867B1 (no) 2011-08-01
PL1651249T3 (pl) 2013-04-30
EP2316473A1 (en) 2011-05-04
US8765675B2 (en) 2014-07-01
CN1856321B (zh) 2012-10-03
ES2436152T3 (es) 2013-12-27
NZ544645A (en) 2009-04-30
AU2008202879B2 (en) 2012-05-24
US7749954B2 (en) 2010-07-06
AU2004262906A1 (en) 2005-02-17
ZA200600373B (en) 2007-01-31
HK1152229A1 (en) 2012-02-24
CA2532565C (en) 2012-05-08
IL173002A (en) 2013-09-30
RU2368390C2 (ru) 2009-09-27
JP2006528152A (ja) 2006-12-14
JP4716987B2 (ja) 2011-07-06
EP1651249A1 (en) 2006-05-03
IS8316A (is) 2006-02-21
PL2316473T3 (pl) 2014-05-30
JP2011121987A (ja) 2011-06-23
US20140271735A1 (en) 2014-09-18
EP1651249B1 (en) 2012-09-12
IL227988A (en) 2016-10-31
IL227988A0 (en) 2013-09-30
TW200518769A (en) 2005-06-16

Similar Documents

Publication Publication Date Title
KR101070036B1 (ko) 골관절염에 대한 칼시토닌의 용도
JP6118107B2 (ja) Ｒａの処置のためのカルシトニンの使用
HK1152229B (en) Use of calcitonin in osteoarthritis
HK1089935B (en) Use of calcitonin in osteoarthritis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20140901

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20150827

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20160831

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180928

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180928

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000